

Product Pipeline

Innovative

Product/Molecule	Licensur	Country	Therapeutic Area	Stage of development
Tafasitamab	Incyte	LATAM	Oncology/Hematology	Pre-Registration ¹
Pemigatinib	Incyte	LATAM	Oncology/Hematology	Pre-Registration
Fostamatinib	Rigel	LATAM	Oncology/Hematology	Pre-Registration
Bijuva™	TXMD	Canada	Other Specialty	Pre-Registration
Imvexxy™	TXMD	Canada	Other Specialty	Pre-Registration

¹ Submitted for regulatory review in Brazil

Branded Generics

Country	Therapeutic Area	Number of molecules	Stage of development	Expected launch year
Argentina	Oncology/Hematology	2	Development	2025
Argentina	Oncology/Hematology	1	Pending Launch	2023
Brazil	Oncology/Hematology	1	Development	2025
Brazil	Other Specialty	1	Development	2025
Colombia	Oncology/Hematology	2	Development	2025-2026
Colombia	Oncology/Hematology	1	Regulatory Review	2023
Colombia	Other Specialty	1	Development	2027
Chile	Oncology/Hematology	3	Development	2024
Mexico	Oncology/Hematology	1	Development	2027
Mexico	Other Specialty	1	Development	2025

